Insights Into Recursion Pharmaceuticals Inc (RXRX) Exposure By Institutions

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.

Stocks Info

Recursion Pharmaceuticals Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Recursion Pharmaceuticals Inc is $2.57B. A total of 17.74 million shares were traded on the day, compared to an average of 23.56M shares.

In the most recent transaction, Gibson Christopher sold 20,000 shares of RXRX for 6.58 per share on Mar 05 ’25. After the transaction, the Chief Executive Officer now owns 1,256,024 company shares. In a previous transaction on Mar 06 ’25, Gibson Christopher sold 20,000 shares at 6.37 per share. RXRX shares that Chief Executive Officer owns now total 1,256,024.

Among the insiders who bought shares, Gibson Christopher acquired of 20,000 shares on Mar 06 ’25 at a per-share price of $6.37. In another insider transaction, Gibson Christopher bought 20,000 shares at $6.58 per share on Mar 05 ’25.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, RXRX has a high of $12.36 and a low of $5.60.

As of this writing, RXRX has an earnings estimate of -$0.52 per share for the current quarter. EPS was calculated based on a consensus of 5.0 estimates, with a high estimate of -$0.39 per share and a lower estimate of -$0.8.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. RXRX’s latest balance sheet shows that the firm has $516.56M in Cash & Short Term Investments as of fiscal 2021. There were $11.48M in debt and $46.66M in liabilities at the time. Its Book Value Per Share was $2.61, while its Total Shareholder’s Equity was $542.94M.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RXRX is Buy with a score of 3.38.

Most Popular

Related Posts